Last reviewed · How we verify
ASP1585
ASP1585 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
ASP1585 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer.
At a glance
| Generic name | ASP1585 |
|---|---|
| Also known as | ILY101, AMG223, Bixalomer, Kiklin (R), LY101 |
| Sponsor | Astellas Pharma Inc |
| Drug class | Androgen receptor degrader (SARD) |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ASP1585 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms. This approach is designed to provide more complete suppression of androgen receptor signaling in hormone-sensitive cancers.
Approved indications
- Castration-resistant prostate cancer (CRPC)
- Hormone-sensitive prostate cancer
Common side effects
- Fatigue
- Hot flashes
- Decreased libido
- Erectile dysfunction
Key clinical trials
- Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis
- Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease
- Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
- Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia (PHASE2)
- A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules (PHASE1)
- Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis (PHASE3)
- A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis (PHASE3)
- Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP1585 CI brief — competitive landscape report
- ASP1585 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI